CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer. Issue 2 (10th April 2015)

• Record Type: Journal Article
• Authors: Wei, Zhe-Wei; Xia, Guang-Kai; Wu, Ying; Chen, Wei; Xiang, Zhen; Schwarz, Roderich E.; Brekken, Rolf A.; Awasthi, Niranjan; He, Yu-Long; Zhang, Chang-Hua
• Is Part Of: Cancer letters. Volume 359:Issue 2(2015)
• Page Start: 335
• Page End: 343
• Publication Date: 2015-04-10
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2015.01.033
• Languages: English
• ISSNs: 0304-3835

Abstract

<abstract abstract-type="author-highlights" id="ab0010"> <title id="st0010">Highlights</title> <sec> <p id="sp0010"> <list id="ulist0010"> <list-item id="u0010"> <label></label> <p id="p0010">The precise role and mechanism of CXCL1 on gastric tumor growth remain unclear.</p> </list-item> <list-item id="u0015"> <label></label> <p id="p0015">CXCL1 is overexpressed in gastric cancer (GC) and correlates with tumor stage and patient survival.</p> </list-item> <list-item id="u0020"> <label></label> <p id="p0020">CXCL1 enhances VEGF expression through the activation of JAK2-STAT3 signaling.</p> </list-item> <list-item id="u0025"> <label></label> <p id="p0025">CXCL1 promotes tumor growth and angiogenesis through the VEGF pathway.</p> </list-item> <list-item id="u0030"> <label></label> <p id="p0030">The CXCL1/CXCR2 pathway might be a promising therapeutic target in GC.</p> </list-item> </list> </p> </sec> </abstract>